{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T21:56:17Z","timestamp":1789250177608,"version":"build-2803163510"},"reference-count":40,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T00:00:00Z","timestamp":1719964800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Traditionally, the treatment of anemia associated with chronic kidney disease (CKD) involves prescribing erythropoiesis-stimulating agents (ESAs) or iron preparations. The effectiveness and safety of ESAs and iron have been established. However, several clinical issues, such as hyporesponsiveness to ESAs or defective iron utilization for erythropoiesis, have been demonstrated. Recently, a new class of therapeutics for renal anemia known as hypoxia-inducible factor (HIF)\/proline hydroxylase (PH) inhibitors has been developed. Several studies have reported that HIF-PH inhibitors have unique characteristics compared with those of ESAs. In particular, the use of HIF-PH inhibitors may maintain target Hb concentration in patients treated with a high dose of ESAs without increasing the dose. Furthermore, several recent studies have demonstrated that patients with CKD with defective iron utilization for erythropoiesis had a high risk of cardiovascular events or premature death. HIF-PH inhibitors increase iron transport and absorption from the gastrointestinal tract; thus, they may ameliorate defective iron utilization for erythropoiesis in patients with CKD. Conversely, several clinical problems, such as aggravation of thrombotic and embolic complications, diabetic retinal disease, and cancer, have been noted at the time of HIF-PH inhibitor administration. Recently, several pooled analyses of phase III trials have reported the non-inferiority of HIF-PH inhibitors regarding these clinical concerns compared with ESAs. The advantages and issues of anemia treatment by ESAs, iron preparations, and HIF-PH inhibitors must be fully understood. Moreover, patients with anemia and CKD should be treated by providing a physiological erythropoiesis environment that is similar to that of healthy individuals.<\/jats:p>","DOI":"10.3390\/ijms25137322","type":"journal-article","created":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T11:35:57Z","timestamp":1720006557000},"page":"7322","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Treatment of Anemia Associated with Chronic Kidney Disease: Plea for Considering Physiological Erythropoiesis"],"prefix":"10.3390","volume":"25","author":[{"given":"Takahiro","family":"Kuragano","sequence":"first","affiliation":[{"name":"Division of Kidney and Dialysis, Hyogo Medical University, Hyogo 663-8501, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,7,3]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1159\/000455166","article-title":"Targeting Hypoxia-Inducible Factors for the treatment of anemia in chronic kidney disease patients","volume":"45","author":"Locatelli","year":"2017","journal-title":"Am. J. Nephrol."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Kuragano, T., Kitamura, K., Matsumura, O., Matsuda, A., Hara, T., Kiyomoto, H., Murata, T., Fujimoto, S., Hase, H., and Joki, N. (2016). ESA Hyporesponsiveness Is Associated with Adverse Events in Maintenance Hemodialysis (MHD) Patients, But Not with Iron Storage. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0147328"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000528696","article-title":"Regional Variation of Erythropoiesis-Stimulating Agent Hyporesponsiveness in the Global Daprodustat Dialysis Study (ASCEND-D)","volume":"54","author":"Macdougall","year":"2023","journal-title":"Am. J. Nephrol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1007\/s10157-022-02227-8","article-title":"Prevalence, treatment status, and predictors of anemia and erythropoietin hyporesponsiveness in Japanese patients with non-dialysis-dependent chronic kidney disease: A cross-sectional study","volume":"26","author":"Tanaka","year":"2022","journal-title":"Clin. Exp. Nephrol."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Hamza, E., Metzinger, L., and Metzinger-Le Meuth, V. (2020). Uremic Toxins Affect Erythropoiesis during the Course of Chronic Kidney Disease: A Review. Cells, 9.","DOI":"10.3390\/cells9092039"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/ki.2014.114","article-title":"Association between hemoglobin variability, serum ferritin levels, and adverse events\/mortality in maintenance hemodialysis patients","volume":"86","author":"Kuragano","year":"2014","journal-title":"Kidney Int."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1093\/ckj\/sfaa054","article-title":"Contemporary management of anaemia, erythropoietin resistance and cardiovascular risk in patients with advanced chronic kidney disease: A nationwide analysis","volume":"13","author":"Evans","year":"2020","journal-title":"Clin. Kidney J."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1681\/ASN.V291405","article-title":"Clinical pharmacology and economics of recombinant human erythropoietin in end-stage renal disease: The case for subcutaneous administration","volume":"2","author":"Besarab","year":"1992","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1053\/j.ajkd.2008.12.030","article-title":"Thrombocytosis in EPO-treated dialysis patients may be mediated by EPO rather than iron deficiency","volume":"53","author":"Vaziri","year":"2009","journal-title":"Am. J. Kidney Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1056\/NEJMoa0908355","article-title":"Ferric carboxymaltose in patients with heart failure and iron deficiency","volume":"361","author":"Anker","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1056\/NEJMoa1810742","article-title":"Intravenous Iron in Patients Undergoing Maintenance Hemodialysis","volume":"380","author":"Macdougall","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1159\/000312381","article-title":"Determinants of hepcidin in patients on maintenance hemodialysis: Role of inflammation","volume":"31","author":"Kuragano","year":"2010","journal-title":"Am. J. Nephrol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.1093\/ndt\/gfq760","article-title":"Hepcidin as well as TNF-\u03b1 are significant predictors of arterial stiffness in patients on maintenance hemodialysis","volume":"26","author":"Kuragano","year":"2011","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s12185-018-2531-2","article-title":"Deregulated iron metabolism in bone marrow from adenine-induced mouse model of chronic kidney disease","volume":"109","author":"Kimura","year":"2019","journal-title":"Int. J. Hematol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"315","DOI":"10.4103\/1319-2442.256838","article-title":"Association of hepcidin and anemia in early chronic kidney disease","volume":"30","author":"Sonkar","year":"2019","journal-title":"Saudi J. Kidney Dis. Transpl."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.numecd.2020.12.018","article-title":"Abnormal iron status is associated with an increased risk of mortality in patients on peritoneal dialysis","volume":"31","author":"Luo","year":"2021","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1093\/ndt\/gfz192","article-title":"Prevalence, correlates and outcomes of absolute and functional iron deficiency anemia in nondialysis-dependent chronic kidney disease","volume":"36","author":"Awan","year":"2021","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/ki.2014.275","article-title":"Data from the Dialysis Outcomes and Practice Patterns Study validate an association between high intravenous iron doses and mortality","volume":"87","author":"Bailie","year":"2015","journal-title":"Kidney Int."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.amjmed.2012.01.015","article-title":"Hemodialysis-associated hemosiderosis in the era of erythropoiesis-stimulating agents: A MRI study","volume":"125","author":"Rostoker","year":"2012","journal-title":"Am. J. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1681\/ASN.2007050606","article-title":"Ferric gluconate reduces epoetin requirements in hemodialysis patients with elevated ferritin","volume":"19","author":"Kapoian","year":"2008","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1159\/000485697","article-title":"Importance of Physiological Erythropoiesis in the Treatment of Chronic Kidney Disease-Associated Anemia","volume":"196","author":"Kuragano","year":"2018","journal-title":"Contrib. Nephrol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1111\/1744-9987.13609","article-title":"Factors affecting the doses of roxadustat vs. darbepoetin alfa for anemia treatment in hemodialysis patients","volume":"25","author":"Akizawa","year":"2021","journal-title":"Ther. Apher. Dial."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1681\/ASN.2020091311","article-title":"Phase 3 Randomized Study Comparing Vadadustat with Darbepoetin Alfa for Anemia in Japanese Patients with Nondialysis-Dependent CKD","volume":"32","author":"Nangaku","year":"2021","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.2215\/CJN.16011219","article-title":"Efficacy and Safety of Daprodustat Compared with Darbepoetin Alfa in Japanese Hemodialysis Patients with Anemia: A Randomized, Double-Blind, Phase 3 Trial","volume":"15","author":"Akizawa","year":"2020","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1056\/NEJMoa1901713","article-title":"Roxadustat treatment for anemia in patients undergoing Long-Term Dialysis","volume":"381","author":"Chen","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/nrm1366","article-title":"Ratcliffe. Oxygen sensing by HIF hydroxylases","volume":"5","year":"2004","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1056\/NEJMoa2025956","article-title":"Safety and efficacy of vadadustat for anemia in patients undergoing dialysis","volume":"384","author":"Eckardt","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1056\/NEJMoa2035938","article-title":"Vadadustat in Patients with Anemia and Non-Dialysis-Dependent CKD","volume":"384","author":"Chertow","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1001\/jamainternmed.2022.0605","article-title":"Efficacy and Safety of Daprodustat for Treatment of Anemia of Chronic Kidney Disease in Incident Dialysis Patients: A Randomized Clinical Trial","volume":"182","author":"Singh","year":"2022","journal-title":"JAMA Intern. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"5361","DOI":"10.1007\/s12325-021-01904-6","article-title":"Roxadustat for the Maintenance Treatment of Anemia in Patients with End-Stage Kidney Disease on Stable Dialysis: A European Phase 3, Randomized, Open-Label, Active-Controlled Study (PYRENEES)","volume":"38","author":"Csiky","year":"2021","journal-title":"Adv. Ther."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"5345","DOI":"10.1007\/s12325-021-01903-7","article-title":"Efficacy and Cardiovascular Safety of Roxadustat in Dialysis-Dependent Chronic Kidney Disease: Pooled Analysis of Four Phase 3 Studies","volume":"38","author":"Barratt","year":"2021","journal-title":"Adv. Ther."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.ekir.2022.01.1045","article-title":"Two Phase 3 Studies on Ophthalmologic Effects of Roxadustat Versus Darbepoetin","volume":"7","author":"Sepah","year":"2022","journal-title":"Kidney Int. Rep."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1093\/ndt\/gfac342","article-title":"Analysis of on-treatment cancer safety events with daprodustat versus conventional erythropoiesis-stimulating agents-post hoc analyses of the ASCEND-ND and ASCEND-D trials","volume":"38","author":"Singh","year":"2023","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"917","DOI":"10.21873\/invivo.13519","article-title":"Hypoxia-inducible factor prolyl hydroxylase inhibitors and hypothyroidism: An analysis of the Japanese Pharmacovigilance Database","volume":"38","author":"Tanaka","year":"2024","journal-title":"In Vivo"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1182\/blood.2019001915","article-title":"Heme-regulated eIF2\u03b1 kinase in erythropoiesis and hemoglobinopathies","volume":"134","author":"Chen","year":"2019","journal-title":"Blood"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1021\/bi101585c","article-title":"Hypoxic induction of human erythroid-specific delta-aminolevulinate synthase mediated by hypoxia-inducible factor 1","volume":"50","author":"Zhang","year":"2011","journal-title":"Biochemistry"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.cca.2019.07.035","article-title":"Variability of red blood cell size predicts all-cause mortality, but not progression to dialysis, in patients with chronic kidney disease: A 13-year pre-ESRD registry-based cohort","volume":"497","author":"Yeh","year":"2019","journal-title":"Clin. Chim. Acta."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s10157-022-02282-1","article-title":"Hematological parameters of anemia and prognosis of non-dialysis-dependent chronic kidney disease: The Fukushima CKD cohort study","volume":"27","author":"Saito","year":"2023","journal-title":"Clin. Exp. Nephrol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.1016\/j.ejim.2012.11.017","article-title":"The relationship between red cell distribution width with erythropoietin resistance in iron replete hemodialysis patients","volume":"24","author":"Afsar","year":"2013","journal-title":"Eur. J. Intern. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e1223","DOI":"10.34067\/KID.0000000000000204","article-title":"Anemia Treatment, Hemoglobin Variability, and Clinical Events in Patients with Nondialysis-Dependent CKD in Japan","volume":"4","author":"Kuragano","year":"2023","journal-title":"Kidney"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/13\/7322\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:09:49Z","timestamp":1760108989000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/13\/7322"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,3]]},"references-count":40,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2024,7]]}},"alternative-id":["ijms25137322"],"URL":"https:\/\/doi.org\/10.3390\/ijms25137322","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,3]]}}}